Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Pfizer Unit Reaches Patent Litigation With Intelliject, Sanofi-Aventis

Mylan Inc. (MYL: Quote) and Pfizer Inc. (PFE: Quote) Thursday announced that Meridian Medical Technologies, a Pfizer subsidiary, has agreed with Intelliject and Sanofi-Aventis to resolve pending patent litigation related to Intelliject's new drug application for its epinephrine auto-injector known as e-cue.

E-cue will be manufactured and marketed by Sanofi-Aventis. Meridian manufactures EpiPen Auto-Injector and Mylan Specialty markets and distributes the product in the United States.

As per the settlement, Intelliject and Sanofi-Aventis may launch e-cue no earlier than November 15, 2012, subject to receipt of final approval from the U.S. Food and Drug Administration.

Click here to receive FREE breaking news email alerts for Mylan Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Stocks showed a lack of direction over the course of the trading day on Friday after failing to sustain an initial upward move. Despite the choppy trading, the Dow once again managed to end the session at a new record closing high. The major averages turned in a mixed performance on the day. President Barack Obama delivered a statement Thursday evening thanking members of Congress for voting to approve legislation granting the U.S. military the authority to train and arm moderate Syrian rebels fighting against the terrorist group known as the Islamic State. While the Conference Board released a report on Friday showing a continued increase by its index of leading U.S. economic indicators in the month of August, the pace of growth showed a significant slowdown compared to the previous month.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.